U.S. FDA Selects ComplianceQuest QRC System to Modernize Enterprise QMS

U.S. FDA Selects ComplianceQuest QRC System to Modernize Enterprise QMS

U.S. FDA Selects ComplianceQuest QRC System to Modernize Enterprise QMS

How Quality Leaders Can Turn Management Reviews into Business Drivers
Tania Ghosh
Tania Ghosh | November 16th, 2026

How Quality Leaders Can Turn Management Reviews into Business Drivers

Quick Summary (TL;DR)

A management review exists so leadership can decide whether the quality management system (QMS) still fits the business and where it needs to improve. There are many organizations out there where it has become a major reporting exercise. Quality teams spend weeks building slides, and executives leave without making a single business decision.

For medical device manufacturers, the stakes went up on February 2, 2026. Under the FDA’s Quality Management System Regulation (QMSR), investigators can now inspect management review records that the old Quality System Regulation (QSR) kept off the table.

The fix starts with the agenda. Put your customers at the top of your priority, track trends instead of activity counts, and check if last quarter’s decisions were carried out. Hold the review every quarter, and let a connected digital QMS pull the data together so the meeting can focus on decisions.

Dr. Joseph A. DeFeo, Chief Quality and Advocacy Officer at ComplianceQuest, lays out this approach in an insightful whitepaper, “Rethinking the Quality, Risk and Compliance Management Review.”

What is a Management Review Meant For?

Dr. Joseph A. DeFeo, who succeeded Dr. Joseph M. Juran at the Juran Institute, compares a good management review to a leadership Gemba Walk. On the shop floor, leaders ask questions, push on assumptions and look for ways to improve the system. A management review does the same, except leadership is walking through the health of the QMS instead of a production line.

ISO 9001 sums up what leadership is checking in these three words –

  • Suitability
  • Adequacy
  • Effectiveness

Simply put, does the QMS still fit the business, fulfil customer and regulatory requirements, and truly work?

Dr. DeFeo adds one more test: can it support the company’s next stage of growth? He sees the review as a working discussion between leadership and the quality team about whether the QMS is helping the business hit its objectives.

The new ISO 9001:2026 is a good reason to ask these questions now. Our ISO 9001:2026 transition guide recommends using management review to check transition readiness and to glean real insight, not just to stay compliant.

Why Do So Many Management Reviews End Without A Decision?

Dr. DeFeo has heard the same complaint for years! One quality leader put it bluntly after a review – “We spent three weeks preparing for a three-hour meeting, and I’m not sure we made a single key business decision.”

Most of that preparation time goes to assembly, because the data sits across different systems:

  • Someone exports spreadsheets
  • Someone else builds slides
  • Every department sends its own report

Sometimes the data is clean and still misleading. Dr. DeFeo refers to this as “watermelon reporting” – green on the outside, red underneath.

As metrics move up the organization, the uncomfortable ones quietly drop out. By the time the dashboard reaches senior leadership, it looks far healthier than the operation behind it.

That defeats the entire purpose of the meeting. As DeFeo puts it, “Leadership doesn’t need better presentations. Leadership needs a truthful view of the business.”

Reviews also tend to celebrate activity. Closing 85 CAPAs or completing 40 internal audits sounds productive. But executives want to know:

  • Did complaints go down?
  • Did process capability improve?
  • Did cycle times get shorter?

A count of closed records can’t answer any of that.

Why Does QMSR Raise the Stakes for Medical Device Management Reviews?

For medical device makers, the QMSR took effect on February 2, 2026, bringing ISO 13485:2016 into 21 CFR Part 820. One change lands squarely on this meeting.

The old QSR, under section 820.180(c), exempted management review records, internal audit reports and supplier audit reports from routine FDA inspection. That exception is gone. The FDA’s QMSR FAQ confirms investigators may review these records, including ones created before the effective date.

In practice, a management review record is now evidence. An all-green deck, or minutes with no decisions and no follow-up, tells an investigator a lot about how top management really oversees the QMS.

ISO 13485 clause 5.6 already defines what the review must cover. What’s new is that the regulator can now see how well you do it.

Device makers aren’t alone here. Management review is also part of ICH Q10 for pharmaceutical quality systems, and of IATF 16949 and AS9100 for automotive and aerospace suppliers.

What Should Leadership Review in a Management Review Meeting?

Dr. DeFeo’s advice is to stop building the agenda around what happened inside the quality department. Build it around what leadership needs to know to make better decisions. The whitepaper breaks that into four lenses.

The Four Lenses of a Decision-Ready Management Review

Lens What to review The question behind it
1. Customer Complaints and feedback, expectation trends, customer impact (for device makers, include post-market surveillance data) Are we meeting expectations, and is it getting better or worse?
2. Operations Product conformity, process capability, audit findings, supplier performance, CAPA trendsWhich direction are the key metrics moving?
3. Follow-through Previous review decisions, action owners, completion and effectiveness Were last quarter’s decisions carried out, and did they work?
4. Business impact Cost of poor quality, time lost to recurring problems, risk What is poor quality costing us?

On operations, the trend tells you more than the total. A closed CAPA proves the paperwork is finished, which is a long way from proving the root cause is gone. To find out, look at how long CAPAs take to close, if the same issues keep coming back, and which departments keep raising corrective actions.

One Question Worth Asking Every Time

“What did we decide last time, and did we actually do it?” Dr. DeFeo says this question alone often shows how well the whole review process is working.

Business impact is where quality leaders get the room’s full attention, because executives care about efficiency and cost as much as effectiveness. In medical devices, that cost runs high.

A 2017 McKinsey analysis estimated the medical device industry’s direct cost of quality at 6.8 to 9.4 percent of sales, or $26 billion to $36 billion a year, with about two-thirds coming from poor quality.

How Often Should Quality Leaders Hold Management Reviews?

Dr. DeFeo recommends holding a management review every three months rather than once a year or every month.

Here’s why:

  • Annual reviews try to squeeze twelve months into one meeting.
  • Monthly reviews rarely show enough change to be worth the time.
  • Quarterly reviews match the rhythm leadership already uses for financial and operational performance, and catch trends while they’re still small.

A good cadence still won’t help if the conversation drifts into the weeds. A management review is the wrong place to look into individual complaints or nonconformances; operational review meetings handle those.

This meeting is for patterns, risks and priorities, and a strong facilitator keeps it there.

How Do Digital QMS Platforms and AI Change the Management Review?

The preparation burdens mostly stem from quality data sitting across separate systems. A digital QMS that connects complaints, CAPAs, audits, supplier quality, training and change control gives leadership one trusted source.

Real-time dashboards and role-based scorecards keep current performance in front of leaders, so nobody rebuilds the picture from spreadsheets each quarter.

AI takes it one step ahead. It can spot emerging trends and unusual patterns, flag data quality issues and surface risks before they grow into business problems. That shifts the review from looking back at what happened to deciding what comes next.

And because every figure traces back to a controlled record, you have an answer ready when an investigator asks where a number came from.

What Should Quality Leaders Do Before the Next Review?

Here are five moves worth adding to your arsenal before the next review:

  • Rebuild the agenda around the four lenses, with customer performance at the top.
  • Open the meeting with last quarter’s decisions and whether each one was carried out.
  • Replace activity counts with trends, such as CAPA cycle time and repeat issues.
  • Put a cost on at least one recurring problem, so leadership sees it in financial terms.
  • If you make medical devices, reread your last set of minutes the way an FDA investigator would.

In Dr. Joseph A. DeFeo’s view, a management review should be judged by:

  • The decisions it produces
  • What those decisions change for customers
  • What they change for the business

Getting there usually starts with one better meeting.

Ready to Modernize Your Management Reviews

Final Words

Under QMSR, the FDA can now inspect management review records, so device makers should write their minutes knowing an investigator may read them. The reviews that hold up start from the decisions leadership needs to make. They track trends rather than activity, because a closed CAPA only proves the paperwork is done.

Frequently Asked Questions

  • It’s a planned meeting where top management checks whether the QMS is still suitable, adequate and effective. ISO 9001 covers it in clause 9.3 and ISO 13485 in clause 5.6. Inputs include customer feedback, audit results, process performance, corrective actions and follow-up from earlier reviews. ISO 13485 adds complaint handling, regulatory reporting and preventive action. Neither standard sets a frequency, but both require the review’s decisions to be recorded.

  • Yes. The old QSR shielded management review, internal audit and supplier audit records from routine inspection under section 820.180(c). The QMSR, effective February 2, 2026, dropped that exception, and the FDA confirms investigators may review these records, including ones created before that date. Treat your minutes, inputs and action logs as inspection-ready, and make sure they show real decisions and real follow-up.

  • Start with customer performance: complaints, feedback and, for device makers, post-market data. Then track trends in product conformity, process capability, audit findings, supplier performance and CAPA cycle times instead of raw activity counts. Check whether actions from the last review were completed and whether they worked. Finish with business impact, including the cost of poor quality and the time lost to recurring problems.

Request a Free Demo

Learn about all features of our Product, Quality, Safety, and Supplier suites. Please fill the form below to access our comprehensive Demo Video.

Please confirm your details

Graphic
AgentQ
AgentQ

Free FDA Intelligence

483s, warning letters, recalls, inspection trends, and FDA guidance, all in one place.

Explore AgentQ
×
spinner
Consult Now

Comments